Business Parks & Science Centres



Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Person › Details

Robert J. (Rob) Wills (Johnson & Johnson (JnJ) (Group))

Wills, Robert J. (Rob) (at JnJ 25 years before Roche)


Organisation Organisation Johnson & Johnson (JnJ) (Group)
Product Product pharmaceutical

GO Therapeutics, Inc.. (10/4/17). "Press Release: GO Therapeutics Appoints Dr. Robert J. Wills to Board of Directors". Cambridge, MA.

GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets, today announced the appointment of Robert J. Wills, Ph.D. to the Company’s Board of Directors.

Dr. Wills is an accomplished, seasoned senior executive whose 37-year career spans directing R&D, business development and alliance management for major pharmaceutical firms and more recently in board roles for small biotechnology companies. Dr. Wills has been a Senior Advisor to the company since June 2015.

Dr. Wills is currently serving in board roles for GTx, Inc; Cymabay Therapeutics, Inc and Parion Sciences. Prior to that, Dr. Wills spent 25-years at Johnson & Johnson in a variety of senior roles in R&D and business development. Dr. Wills also worked ten-years in pharmaceutical drug development at Hoffmann-LaRoche.

“We are very pleased to have Rob join GO’s Board of Directors,” said Constantine Theodoropulos, Chief Executive Officer, GO Therapeutics. “As we chart GO’s growth path, we will benefit greatly from Rob’s ongoing board experience, extensive business development and R&D experience.”

Dr. Wills added, “GO Therapeutics is an exciting company that has an opportunity to play an important role in the advancement of bispecific antibodies for T cell-redirection therapy, antibody-drug conjugates, and immune-based cell therapies. I look forward to transitioning to a board role and working closely with the GO Therapeutics team to help achieve their strategic vision for the company.”

About GO Therapeutics

GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics’ cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bi-specific T-cell engagers and immune-based cell therapies. The company’s scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA.

Record changed: 2018-10-11


Picture [LSUS] – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSUS] – The Business Web Portal 600x60px

» top